Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, Nataraj S, Deonarine LD, Augello MA, Sailer V et al..
2017.
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.. Cancer Cell. 31(3):436-451.
Svensson MA, Lafargue CJ, MacDonald TY, Pflueger D, Kitabayashi N, Santa-Cruz AM, Garsha KE, Sathyanarayana UG, Riley JP, Yun CS et al..
2011.
Testing mutual exclusivity of ETS rearranged prostate cancer.. Lab Invest. 91(3):404-12.
Perner S, Mosquera J-M, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM et al..
2007.
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.. Am J Surg Pathol. 31(6):882-8.
Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera J-M, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG et al..
2006.
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.. Cancer Res. 66(17):8337-41.
Rubin MA.
2004.
Using molecular markers to predict outcome.. J Urol. 172(5 Pt 2):S18-21;discussionS21-2.